https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/305 Sat, 04 Jul 2026 01:58:23 GMT 2026-07-04T01:58:23Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/212766 Title: Cross-neutralizing antibody responses among individuals with or without bivalent vaccine: a six-month prospective cohort study Authors: Cha, Hye Hee; Kim, Ji Yeun; Kim, Seung Beom; Cha, Junho; Kwon, Ji-Soo; Kim, Woori; Son, Ju Yeon; Jang, Choi Young; Kim, Min-Chul; Lim, So Yun; Kim, Sung-Han Abstract: Background/Aims: Although the COVID-19 pandemic has officially ended, SARS-CoV-2 continues to circulate with periodic surges and may exhibit seasonal patterns. Understanding the importance of prompt immunization, particularly in individuals with prior infection, is crucial for developing future vaccination protocols. This study aimed to assess the durability and breadth of neutralizing antibody (nAb) responses against Omicron subvariants based on infection and bivalent vaccination status. Methods: In this six-month prospective cohort study, we evaluated nAb responses to the original SARS-CoV-2 strain (D614G), as well as Omicron subvariants BA.4/5 and XBB.1.5 variants, in 79 healthcare workers stratified by prior Omicron infection and bivalent vaccination status. Blood samples were collected at baseline, 3 months, and 6 months, and nAb titers were measured using an optimized pseudovirus neutralization assay. Results: At 3 months, individuals with prior Omicron infection followed by bivalent vaccination showed significantly higher nAb titers against BA.4/5 and XBB.1.5 compared to those with infection alone or vaccination alone. At 6 months, the highest titers persisted in the group with both prior infection and bivalent vaccination, while titers declined in previously infected but unvaccinated individuals. Notably, individuals with prior infection alone exhibited comparable nAb titers to infection-naïve vaccinated individuals, suggesting limited durability of infection-induced immunity without vaccine-induced boosting. Conclusions: These findings underscore the importance of timely vaccination, even among previously infected individuals, to ensure sustained humoral immunity and broader cross-nAb responses against emerging SARS-CoV-2 variants. Fri, 01 May 2026 00:00:00 GMT https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/212766 2026-05-01T00:00:00Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/212937 Title: CEPI Workshop Report: Applying Disease X Vaccine Library and Knowledge Base Approaches to Severe Fever with Thrombocytopenia Syndrome (SFTS) Authors: Kitano, Mitsutaka; Shim, Byoung-Shik; Sasaki, Hitoshi; Lovell, Jonathan F.; Kim, V. Narry; Kim, Rachel; Huang, Wei-Chao; Kim, Sun Bean; Park, Woo-Jung; Bettis, Alison A.; Lee, Keun Hwa; Takamatsu, Yuki; Castillo-Olivares, Javier; Yoshikawa, Rokusuke; Gollihar, Jimmy D.; Segall-Shapiro, Thomas H.; Spencer, Keith C.; Malin, Gene; Gerhards, Nora M.; Brangel, Polina; Dalland, Lindi; Kwon, Soo-Young; Kaneko, Satoshi; Morita, Kouichi; Song, Manki; Endy, Timothy Abstract: On 9–10 December 2025, the Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI) convened a workshop in Seoul under CEPI’s Disease X Program. The primary objective was to identify existing gaps needing to be filled and streamline vaccine development and preparedness for Severe Fever with Thrombocytopenia Syndrome (SFTS). CEPI’s partners and experts discussed a multifaceted agenda, ranging from understanding the evolving epidemiology to the refinement of animal models and immunological assay harmonization. Key outcomes included the refinement of Target Product Profiles (TPPs) specifying use cases for both peacetime and outbreak contexts, alongside a recommendation for a core immunoassay panel aimed at harmonizing evaluation frameworks and mitigating the challenges posed by low SFTS prevalence. Integration of the One Health approach emerged as a critical strategy for SFTS prevention, complemented by proactive regulatory engagement to compress vaccine development timelines. This report summarizes these key insights from the workshop, delineating a strategic framework for delivering safe, effective, and accessible vaccines for SFTS and broader Disease X threats. Wed, 01 Apr 2026 00:00:00 GMT https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/212937 2026-04-01T00:00:00Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/212166 Title: Multiple organ dysfunction score for assessing patients with severe fever with thrombocytopenia syndrome Authors: Yoo, Jeong Rae; Heo, Sang Taek; Kim, Misun; Kim, Miyeon; Kang, Myeong Jin; Kim, Sora; Oh, Hyunjoo; Oh, Suhyun; Kang, Su Yeon; Lee, Keun Hwa Abstract: Background/purpose: Severe Fever with Thrombocytopenia Syndrome (SFTS) is a tick-borne viral disease with high mortality rates. The Multiple Organ Dysfunction Score (MODS) is used for assessing organ dysfunction and predicting outcomes in critically ill patients. We aimed to evaluate the relationship between MODS and clinical outcomes in patients with SFTS. Methods: We conducted an observational cohort study involving patients with SFTS between 2013 and 2023. Patients were categorized into four groups (0–1, 2–3, 4–5, and ≥6) based on their MODS at admission and day 7. Results: Among the 97 patients with SFTS, the mean age was 62.4 years with 53.6 % males. The 7-day mortality rate for patients with MODS ≥6 was 37.5 %, compared to 0 % for those with MODS 0–1. Patients with MODS scores of 4–5 also showed high 7-day mortality (25.0 %). Higher MODS scores were significantly associated with elevated mortality rates. Viral loads and IL-6 levels were significantly higher in patients with MODS ≥6 than those with lower scores. Conclusions: MODS is a valuable prognostic tool for assessing disease severity in patients with SFTS. Monitoring changes in MODS could improve outcomes by identifying patients who need aggressive treatment early in the disease course. Wed, 01 Apr 2026 00:00:00 GMT https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/212166 2026-04-01T00:00:00Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/216491 Title: Plateauing Incidence of SFTS in Korea Authors: 이근화 Mon, 16 Mar 2026 00:00:00 GMT https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/216491 2026-03-16T00:00:00Z